

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		200571018	
Date Submitted: March 8, 2006		Application Number	Unassigned
(use as many sheets as necessary)		Filing Date	3/8/2006
Sheet	1	First Named Inventor	Mikio SHOJI
	of 1	Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	023312-0122

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
A2	WO	94/17197	A1	Takeda Chem Ind., Ltd.	08/04/1994	= A1	A
A3	WO	96/25435	A1	Bayer Corporation	08/22/1996		
A4	WO	00/77178	A1	Boston Biomedical Research Institute	12/21/2000		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A5	BARD et al., "Peripherally administered antibodies against amyloid $\beta$ -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , ugust 2000, Vol. 6, No. 8, pp. 916-919.	
	A6	DEMATTO et al., "Peripheral anti- $\text{A}\beta$ antibody alters CNS and plasma $\text{A}\beta$ clearance and decreases brain $\text{A}\beta$ burden in a mouse model of Alzheimer's disease," <i>PNAS</i> , July 17, 2001, Vol. 98, No. 15, pp. 8850-8855.	
	A7	DODART et al., "Immunization reverses memory deficits without reducing brain $\text{A}\beta$ burden in Alzheimer's disease model," <i>Nature Neuroscience</i> , May 2002, Vol. 5, No. 5, pp. 452-457.	
	A8	HOCK et al., "Generation of antibodies specific for $\beta$ -amyloid by vaccination of patients with Alzheimer disease," <i>Nature Medicine</i> , November 2002, Vol. 8, No. 11, pp. 1270-1275.	
	A9	VEHMAS et al., " $\beta$ -Amyloid Peptide Vaccination Results in Marked Changes in Serum and Brain $\text{A}\beta$ Levels in APPswe/PS1 $\Delta$ E9 Mice, as Detected by SELDI-TOF-Based ProteinChip® Technology," <i>DNA and Cell Biology</i> , 2001, Vol. 20, No. 11, pp. 713-721.	
	A10	WILCOCK et al., "Intracranially Administered Anti- $\text{A}\beta$ Antibodies Reduce $\beta$ -Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation," <i>The Journal of Neuroscience</i> , May 1, 2003, Vol. 23, No. 9, pp. 3475-3751.	

Examiner Signature	/Gregory Emch/	Date Considered	03/16/2009
--------------------	----------------	-----------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. <sup>2</sup>See attached, the kind of U.S. Patent documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3). <sup>4</sup>Enter name of the inventor(s). <sup>5</sup>Enter name of the assignee(s). <sup>6</sup>Enter name of the first named attorney or agent by the two-letter code.

<sup>2</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>3</sup>Applicant is to place a check mark here if *Fantastic Iquacurá Translation* is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**